5.4 GIP and GLP-1 effects on lipid and glucose metabolism in adipose tissue and liver Fat and liver are two organs that play key roles in lipid and glucose metabolism, working together in concert and complimentarily to maintain lipid and glucose homeostasis
Hydration and Kidney Function During COVID-19 Treatment Maintaining adequate hydration becomes critical when you're managing both a viral infection and a medication that can reduce appetite and fluid intake
206,487 These changes lead to a reduction in the production of non-esterified fatty acids (LCFAs) and glucose, as well as a decrease in the synthesis of VLDL (Very Low-Density Lipoprotein)
Breaking News: Oral Wegovy 25mg Pill Set to Be Approved by End of 2025 Novo Nordisk Confirms FDA Submission for High-Dose Oral Wegovy (semaglutide) GLP-1 Receptor Agonist Novo Nordisk has confirmed it has submitted a high-dose version of its oral semaglutide (currently marketed for type 2 diabetes as the brand, Rybelsus) for FDA approval as a treatment for obesity, supported by strong clinical trials data where body mass index (BMI) was used as a key measure to evaluate body weight reduction and health improvements, with many participants having at least one weight related comorbidity, such as hypertension or dyslipidemia (a metabolic disorder characterized by abnormally high or low amounts of any or all lipids or lipoproteins in the blood)

In vitro studies demonstrate that treatment with the peptide BPC-157 increases GHR mRNA and protein levels in a dose- and time-dependent manner, enhancing the fibroblasts responsiveness to growth hormone and promoting cell proliferation essential for tendon healing
Retatrutide is an injectable peptide being described as a potential breakthrough in weight management